Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
程序性死亡配体 1 抑制剂度伐利尤单抗联合聚（ADP-核糖）聚合酶抑制剂奥拉帕尼或血管内皮生长因子受体 1-3 抑制剂西地尼布治疗女性癌症的安全性和临床活性：一项剂量递增的 I 期研究
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2016.72.1340
Lee, Jung-Min; Cimino-Mathews, Ashley; Peer, Cody J; Zimmer, Alexandra; Lipkowitz, Stanley; Annunziata, Christina M; Cao, Liang; Harrell, Maria I; Swisher, Elizabeth M; Houston, Nicole; Botesteanu, Dana-Adriana; Taube, Janis M; Thompson, Elizabeth; Ogurtsova, Aleksandra; Xu, Haiying; Nguyen, Jeffers; Ho, Tony W; Figg, William D; Kohn, Elise C
